Praxis Precision Medicines Receives FDA Rare Pediatric Disease Designation for Relutrigine in Dravet Syndrome

Praxis receives FDA designation for relutrigine in Dravet syndrome, plans all-DEE trial, emphasizing commitment to rare neurological disorders.

Quiver AI Summary

Praxis Precision Medicines, Inc. has announced that the U.S. FDA has granted Rare Pediatric Disease Designation for its drug relutrigine in treating Dravet syndrome, a severe genetic epilepsy often linked to SCN1A mutations. This designation, the third for relutrigine, reinforces the company’s commitment to addressing needs in rare neurological disorders. Encouraging clinical data shows relutrigine's effectiveness in reducing seizure frequency and improving patients' quality of life. Praxis plans to begin an all-DEE trial named EMERALD in the first half of 2025, with additional studies underway for SCN2A and SCN8A patients, highlighting the potential for relutrigine to be a significant new treatment option for those with limited therapies.

Potential Positives

• Praxis has received Rare Pediatric Disease Designation from the FDA for relutrigine in Dravet syndrome, highlighting the company's commitment to addressing unmet needs in rare neurological disorders.
• This designation potentially allows Praxis to obtain a priority review voucher, which could expedite the review process for future drug applications, streamlining market access.
• Encouraging clinical data for relutrigine has been shared, indicating significant reductions in seizure frequency and improvements in patient quality of life, which enhances the product's value proposition.
• The initiation of an all-DEE trial (EMERALD) in 1H2025 demonstrates Praxis's proactive approach to clinical development and expansion of its therapeutic scope in treating severe conditions like Dravet syndrome.

Potential Negatives

• Although relutrigine has received Rare Pediatric Disease Designation, the company may face challenges in demonstrating the drug's efficacy and safety in future clinical trials, which could impact its market potential.
• The press release emphasizes the encouraging data from previous studies, but the reliance on preliminary and ongoing study outcomes poses a risk if final results do not meet expectations.
• The mention of significant cognitive and developmental impairments associated with Dravet syndrome may raise concerns among stakeholders about the complexity and severity of the condition, impacting perceptions of the company's product's potential success.

FAQ

What is Dravet syndrome?

Dravet syndrome is a severe, genetic epilepsy that begins in early childhood, characterized by frequent, prolonged, and treatment-resistant seizures.

What does Rare Pediatric Disease Designation mean?

Rare Pediatric Disease Designation signifies that a treatment is aimed at serious conditions affecting children, offering potential expedited review processes by the FDA.

What is relutrigine used for?

Relutrigine is being developed as a treatment for developmental and epileptic encephalopathies, specifically targeting conditions like SCN2A and SCN8A DEEs.

When is the EMERALD trial expected to start?

The EMERALD trial, which will include Dravet syndrome patients, is planned to begin in the first half of 2025.

What are the expected benefits of relutrigine?

Relutrigine aims to reduce seizure frequency and improve overall seizure control in patients with specific genetic epilepsy conditions.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$PRAX Insider Trading Activity

$PRAX insiders have traded $PRAX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $PRAX stock by insiders over the last 6 months:

• ALEX NEMIROFF (General Counsel and Secretary) sold 8,239 shares.
• LAUREN MASTROCOLA (Principal Accounting Officer) sold 5,188 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$PRAX Hedge Fund Activity

We have seen 77 institutional investors add shares of $PRAX stock to their portfolio, and 83 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• CAPITAL RESEARCH GLOBAL INVESTORS added 997,094 shares (+inf%) to their portfolio in Q3 2024
• RA CAPITAL MANAGEMENT, L.P. removed 473,644 shares (-38.3%) from their portfolio in Q3 2024
• ORBIMED ADVISORS LLC removed 460,512 shares (-100.0%) from their portfolio in Q2 2024
• VESTAL POINT CAPITAL, LP removed 440,000 shares (-100.0%) from their portfolio in Q3 2024
• PERCEPTIVE ADVISORS LLC added 413,805 shares (+55.2%) to their portfolio in Q3 2024
• DEEP TRACK CAPITAL, LP removed 389,546 shares (-100.0%) from their portfolio in Q3 2024
• ADAGE CAPITAL PARTNERS GP, L.L.C. removed 280,000 shares (-24.7%) from their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A

This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A and SCN8A DEEs

Praxis plans to initiate an all-DEE trial (EMERALD), inclusive of Dravet syndrome, in 1H2025

BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) --


Praxis Precision Medicines


, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for relutrigine in Dravet syndrome.

“We are thrilled to have been granted rare pediatric disease designation for relutrigine in Dravet syndrome. This milestone reflects our commitment to addressing critical unmet needs in rare neurological disorders and underscores the potential of relutrigine as a meaningful new option for patients and families affected by this debilitating developmental and epileptic encephalopathy. The designation builds upon encouraging clinical data demonstrating relutrigine’s ability to reduce seizure frequency and improve overall seizure control, highlighting our dedication to advancing innovative therapies that can significantly impact quality of life for those with limited treatment options,” said Marcio Souza, president and chief executive officer.

Rare pediatric diseases are defined by the FDA as serious or life-threatening conditions primarily affecting children under 18, with fewer than 200,000 cases in the U.S. A key benefit of obtaining a RPDD is the potential to receive a priority review voucher following FDA approval of a product with RPDD if the marketing application submitted for the product satisfies certain conditions. These vouchers can significantly expedite the review process for future New Drug Applications or biologic license applications.

In September, and updated at the recent 2024 American Epilepsy Society Annual Meeting, Praxis shared results for relutrigine in SCN2A and SCN8A patients in cohort 1 of the EMBOLD study that showed:

• 
  Placebo-adjusted monthly motor seizure reduction of 46% during the double-blind period
  


• 
  Over 30% of patients achieved seizure freedom status while on relutrigine
  


• 
  Meaningful gains observed in alertness, communication and seizure severity
  


• 
  77% reduction in median seizure rate seen for patients in the long-term extension
  

Based on the results of this study, Praxis has initiated and is enrolling patients in a second, registrational cohort for SCN2A and SCN8A patients, expecting topline results in the first half of 2026.

About Relutrigine (PRAX-562)



Relutrigine is a first-in-class small molecule in development for the treatment of developmental and epileptic encephalopathy (DEE) as a preferential inhibitor of persistent sodium current, shown to be a key driver of seizure symptoms in SCN2A-DEE and SCN8A-DEE. Relutrigine’s mechanism of sodium channel modulation is consistent with superior selectivity for disease state sodium channel (NaV) channel hyperexcitability. In vivo studies of relutrigine have demonstrated dose-dependent inhibition of seizures up to complete control of seizure activity in SCN2A, SCN8A and other DEE mouse models. Relutrigine has been generally well-tolerated in three Phase 1 studies and has demonstrated biomarker changes indicative of NaV channel blocking effects. Relutrigine has received Orphan Drug Designation (ODD) and RPDD from the FDA, and ODD from the European Medicines Agency for the treatment of SCN2A-DEE and SCN8A-DEE. To learn more about the EMBOLD study, please visit


https://www.emboldstudy.org/



.

About Dravet Syndrome



Dravet syndrome is a severe, progressive genetic epilepsy that typically begins within the first year of life, marked by frequent, prolonged, and treatment-resistant seizures. Beyond seizures, the condition often leads to intellectual disability, developmental delays, movement and balance difficulties, speech and language impairments, growth abnormalities, sleep disturbances, autonomic nervous system dysfunction, and mood disorders. Classified as a developmental and epileptic encephalopathy, Dravet syndrome is associated with significant cognitive and developmental impairments. Patients with this condition also face an elevated risk of early mortality, including due to sudden unexpected death in epilepsy (SUDEP).

About Praxis



Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit


www.praxismedicines.com


and follow us on


Facebook


,


LinkedIn


and


Twitter/X


.

Forward-Looking Statements



This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis’ future expectations, plans and prospects, including, without limitation, statements regarding the anticipated timing of our clinical trials and the development of our product candidates, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.

The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical trials; preliminary analyses from ongoing studies differing materially from final data from preclinical studies and completed clinical trials; the expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials; and other risks concerning Praxis’ programs and operations as described in its Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Reports on Form 10-Q and other filings made with the Securities and Exchange Commission. Although Praxis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.